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Summary 
We have identified amino acid residues within the evolutionarily conserved 1 domain of the 
o~-chain (CD11a) of the leukocyte integrin leukocyte function-associated antigen (LFA)  1 that 
are critical for intercellular adhesion molecule (ICAM) 3 (CD50) binding. ICAM-3, a ligand of 
LFA-1, is thought to mediate intercellular adhesion essential  for the initiation of immune re- 
sponses.  Using a panel of human/murine I domain chimeras and point mutants, we observed 
that the Ile-Lys-Gly-Asn motif, located in the NH2-terminal part of the CDlla I domain, is 
required for ICAM-3 but not ICAM-1 binding. These findings demonstrate that the I domain 
of CD1 la contains distinct functional subdomains for ligand specific binding. An aspartic acid 
located at position 137, which is essential  to ICAM-1/LFA-1 interactions (Edwards, C.P., M. 
Champe,  T.  Gonzalez, M.E.  Wessinger,  S.A.  Spencer, L.G. Presta, P.W.  Berman, and S.C. 
Bodary. 1995.J. Biol. Chem. 270:12635-12640), was also critical for ICAM-3 binding, whereas 
Ser at position 139 did not effect ICAM-1 or ICAM-3 binding. A synthetic peptide containing 
the Ile-Lys-Gly-Asn motif inhibited ICAM-3-dependent adhesion and proliferation of T  cells 
at micromolar concentrations, suggesting that this peptide interferes with immune recognition. 
These observations underscore the importance oflCAM-3 in leukocyte function, and may lead 
to development of a new category of immunosuppressive agents. 
T 
he  integrin  leukocyte  function-associated  antigen 
(LFA)  1 (CDlla/CD18)  is a leukocyte-specific adhe- 
sion receptor that modulates adhesive interactions and sig- 
naling  functions  in  the  immune  system  (1-3).  LFA-1 
mediates cell--cell adhesion upon binding to its ligands  in- 
tercellular adhesion molecule (ICAM)  1 (CD54),  ICAM-2 
(CD102), or ICAM-3  (CD50)  (4--8). Several studies  (9--13) 
have demonstrated that activation of LFA-1 is required for 
adhesion, and that this can be induced in vitro by engage- 
ment  of the  TCtL-CD3  complex.  Altematively,  LFA-1 
can be activated by exposure to divalent cations (Mn  2+) or 
treatment with activating mAbs to CDlla or CD18. 
Although LFA-1 binding sites have been located in the 
NH2-terminal Ig domains oflCAM-1 and -3 (14-16), pre- 
cise  determination of the ligand-binding sites in LFA-1 is 
still lacking. It has been postulated that the 200-amino acid 
inserted or 'T' domains, which are found in the oe chains of 
integrins  (LFA-1  [CD11a,  oiL],  MAC-1  [CD11b,  aM], 
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p150,95  [CDllc,  otX],  VLA-1  [otl],  VLA-2  [oe2], and 
otEI37) and are homologous to the type A domains ofvon 
Willebrand  factor,  cartilage  matrix-binding  protein,  and 
complement factor B  (17,  18), are essential  to ligand bind- 
ing (19-23). The observations that most blocking mAbs to 
CD1 la map to the I domain (22-24) and that recombinant 
I  domains  both  inhibit  integrin-mediated  adhesion  and 
possess ligand-binding activity (19-21) underscore the role 
of the I domain in ligand binding. 
In this study a panel of human/murine CD1 la I domain 
mutants were used to identify amino acids that were essen- 
tial  for the binding of LFA-1  to  ICAM-3.  We  observed 
that residues located in the NH2-terminal portion of the I 
domain ofCD1 la are critical for ICAM-3 binding, but not 
for ICAM-1 binding. 
Materials  and Methods 
Antibodies.  Function-blocking  mAbs directed against human 
CDlla NKI-L15 (11), human CD18  (MHM23)  (25), and mu- 
rine CD1 la (M17) (26) were used. mAbs R.ek-I  (anti-ICAM-1; 
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M.E., S.J. van Vliet, Y. van Kooyk, and C.G. Figdor, manuscript 
in preparation) were used to inhibit LFA-1/ICAM-1 or LFA-1/ 
ICAM-3 interactions, respectively. For cell adhesion studies, the 
activating antibody KIM185,  directed against CD18  (12),  was 
used. The mAb T3b, directed against CD3  (27),  was used for T 
cell costimulation assays. 
Generation of CD 1 l a I Domain Mutants.  The generation of hu- 
man/mouse  (H/M)  chimeras, the  I domain point mutants,  and 
mu3, has been described previously (24, 28). mu I and mu2 were 
generated by overlap extension PCIL.  Briefly, using full-length 
human  CD11a  cDNA  (piLK LFAotm)  and mu3  cDNA as tem- 
plates, the  NH 2-  and  COOH-terminal  halves of the  mul  and 
mu2 1 domains were generated by PCIL (mul: for residues 125- 
234, mu3 was used, and for residues 235-308, pR.K LFAcxm was 
used; mu2: for residues 125-234, pRK LFA~m was used, and for 
residues 235-308,  mu3  was used.) The Bglll at residue 297  was 
removed from the mul  I domain. The two halves of mul  and 
mu2 were joined by overlapping extension PCIL and cloned into 
the  CDlla at the  appropriate I  domain restriction sites  (Narl, 
BglIl: mul; Narl, PflMl: mu2). 
Expression of CD 1 la I Domain Mutants in 293 Cells.  Mutated 
CD1 la and wild-type CDI8 cDNAs were cloned into the ILK 5 
and ILK 7  expression plasmids .and transfected into the 293  hu- 
man  kidney adenocarcinoma cell line using a  standard calcium 
phosphate coprecipitation method (29).  Transfection e~ciencies 
ranged from 20 to 70%. After 3 d, transfectants were harvested by 
EDTA (5 rnM) treatment and were assayed for adhesion to ICAM-1 
and  ICAM-3.  Staining of the  transfectants  with  various  anti- 
LFA-I mAbs revealed that the mutations did not affect the overall 
conformation of the LFA-I heterodimer (28) (data not shown). 
Adhesion to ICAM-I and ICAM-3.  ICAM-1 and ICAM-3 fu- 
sion proteins consisting of  the five domains oflCAM-1 or ICAM-3 
fused to a human lgG1 Fc fragment (ICAM-1Fc, ICAM-3Fc, re- 
spectively) were isolated from supernatants of L cell cultures sta- 
bly transfected with plCAM-IFc and plCAM-3Fc, respectively 
(7, 16). Culture supematant was purified by protein A column af- 
finity chromatography and eluted with  3.5  M  MgCI  2 and  10% 
glycerol. 96-well plates (Maxisorb; Nunc,  ILoskilde, Denmark) 
were precoated with 4 Ixg/ml goat anti-human Fc (Jackson  Im- 
munoiLesearch  Laboratories, Inc.,  West Grove,  PA)  for 2  h  at 
37~  and blocked with 1% BSA (Boehringer Mannheim, Mann- 
helm,  Germany)  (1  h  at  room  temperature).  ICAM-IFc  or 
ICAM-3Fc proteins were coated overnight at 4~  or at 37~  for 
2  h,  at  a  concentration  of 200  ng/well.  Transfected 293  cells 
(200,000  cells/well)  were  added  in  adhesion  buffer  (0.14  M 
NaCI, 0.02  M  Hepes, 0.2% glucose,  1 mM MgCI2,  and  1 mM 
CaCI2),  with the anti--CD18-activating mAb KIMI85  (12)  and 
allowed to adhere for 1.5 h at 37~  Nonadherent cells were re- 
moved by washing three times with PBS, and cell attachment was 
measured  using  the  PNAG  (P-nitrophenyl-N-acetyl-13-D-glu- 
cosaminide) method  of Landegren  (30).  The  mean  OD405  of 
triplicate wells was determined and corrected for the expression 
levels ofCD1 la/CD18 on the distinct transfectants.  For compar- 
ison 50,000  cells gave an average OD of 1.  For adhesion of the 
human T  cell line HSB (obtained from American Type Culture 
Collection,  ILockville,  MD),  cells  (40,000/well)  were  labeled 
with StCr for 45 n'fin at 37~  Cells were incubated with different 
concentrations of synthetic peptides followed by activation with 
KIMI85.  Subsequendy, cells were  incubated on  ICAM-1Fc- or 
ICAM-3Fc---coated plates for 30 rain at 37~  in the presence of 
peptides and KIM185. Nonadherent cells were removed by three 
washes  with adhesion buffer, adhering cells were lysed with  1% 
Triton  X-100,  and  radioactivity was  quantified.  Results are ex- 
pressed a.s the mean percentage of adhesion of triplicate wells. 
Proliferation Assay.  96-well plates were coated with subopti- 
mal concentrations ofanti-CD3 antibodies (T3b, 10 ng/well, I h at 
37~  followed by goat anti-human Fc (400 ng/well, 1 h at 37~ 
1%  BSA  (100  I~l/well,  30  min  at  37~C) and  ICAM-1Fc  or 
ICAM-3Fc proteins (100 ng/well, 1 h at 37~  ILestmg PBL ob- 
tained by centrifugal elutriation from normal donors as described 
previously (31) were added (100,000 cells/well) and cultured for 
3  d.  On  day 3,  cells were pulsed for  16  h  with  [3H]thymidine 
(1.52  TBq/mmol,  0.5  ~Ci/well;  Amersham  Corp.,  Arlington 
Heights, 1L), and uptake was quantified to measure ICAM-1- or 
ICAM-3-dependent  proliferation.  To  determine  whether  in- 
duced proliferation was LFA-1 and ICAM-I specific, ceils were 
cultured in the presence of function-blocking antibodies at a con- 
centration of 10 Ixg/rnl. 
Results and Discussion 
Despite  the  high  sequence  homology  between  human 
and  mouse  LFA-1,  murine  LFA-1  does  not  bind  human 
ICAM-1  (32). Exploiting this species specificity, we deter- 
mined that substitution of murine I domain sequences into 
human  CDlla  abolished  the  ability  of  LFA-1  to  bind 
ICAM-1  (28).  In this study, we adopted a  similar strategy 
to  determine  the  role  of I  domain  sequences  in  LFA-1/ 
ICAM-3  interactions.  A  panel of H/M  CDlla  I  domain 
mutants  was  used,  some  of which  correspond to  epitopes 
recognized by CD1 la blocking mAbs (24), to identify amino 
acids that were essential for the binding of LFA-1 to ICAM-3 
(Fig. 1).  The capacity of 293  cells transfected with cDNAs 
encoding chimeric CD1 la and human CD18 to bind puri- 
fied human  ICAM-1Fc and ICAM-3Fc is shown  in Fig. 2 
A.  Wild-type  human  CDlla/CD18  transfectants  bound 
both ICAM-1 and ICAM-3. As had been previously shown 
with ICAM-1  (28),  the mu3  chimera (which contains the 
complete murine I domain) did not bind human ICAM-3. 
FACS  |  analysis, using  the  M17,  NKI-L16,  and  MHM23 
rnAbs (11, 25, 26), showed that the mu3 chimera contains 
the  expected murine  I  domain  epitopes as well as human 
CD1 la and CD18 epitopes, suggesting that this heterodimer 
was correctly folded (28). Thus it appeared that the I domain 
of murine LFA-1 lacked the binding site(s) for ICAM-3 as 
well as ICAM-1. We also observed that mul  (which con- 
tains  the  NH2-terminal  portion  of the  murine  I  domain) 
bound  ICAM-1  but  not  ICAM-3,  whereas  mu2  (which 
contains the COOH-terminal portion of the murine I do- 
main) bound to both ICAM-1 and ICAM-3. We conclude 
that the NH2-terminal portion of the human I domain con- 
tains residues critical to ICAM-3 binding, and that ICAM-I 
and  1CAM-3 bind to distinct sites within the  I  domain of 
LFA-1.  Precise mapping of residues involved in  ICAM-1 
binding is in progress. 
To  precisely  locate  the  ICAM-3  binding  site  in  the 
NH2-terminal portion of the I domain, we tested the abil- 
ity of seven H/M  chimeras to bind ICAM-3.  (Fig. 2) The 
overall conformation  of these  H/M  LFA-I  chimeras was 
intact and did not affect ICAM-1  binding (24,  28).  Of all 
H/M  chimeras tested, only H/M53,  in which  the human 
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Figure  1.  Amino acid sequences of the murine and human CD11 a I domains and the H/M I dommn chimeras and point mutants. Schematic represen- 
tation of CDlla  with the location of the I domain and the metal binding (EF hand) domains. Chimeras were generated in which the complete human I 
domain was replaced with the corresponding murine residues (amino acids 125-311;  mu3),  or in which the NH2-terminal  portion of the human I do- 
main (amino acids 125-222;  mul) or the COOH-tenninal  portion of the human I domain (amino acids 223-311;  mu2) were exchanged for the murine 
I domain residues. H/M  chimeras (H/M48-54,  I126M, K127A, G128A, N129K)  contained from one to five murine residues substituted for the human 
I domain sequences  (24).  The Ala substitutions for conserved residues are shown for the constructs D137A and $139A.  The human residues are repre- 
sented by a dash, and where the sequence differs  from the human sequence, the residue is shown. All chimeric proteins and H/M  mutants were expressed 
in the human kidney cell line 293 as LFA-1  (CD11a/CD18)  heterodimers. 
Ile-126 and Asn-129 were replaced with murine residues 
Met and Lys, respectively, completely abrogated adhesion 
to ICAM-3 (Fig. 2 B). In contrast, the adhesion of  this mu- 
tant  to a wide range of concentrations of ICAM-1 showed 
identical  binding  as  that  of wild-type  CD11a  (data  not 
shown). This indicates that the loss of binding of H/M53 
to ICAM-3  was not due to the low afl]nity of ICAM-3, 
compared with  ICAM-1,  for LFA-1.  Point mutations  of 
Ile-126 and Asn-129 revealed that only the replacement of 
Asn with Lys at position 129 dramatically reduced the ad- 
hesion to ICAM-3. When Lys-127 and Gly-128, which are 
conserved between the human and mouse, were mutated 
to Ala, only the Lys-127 mutation led to reduced binding 
to ICAM-3.  These data demonstrate that residues critical 
for ICAM-3 binding are located in the NH2-terminal por- 
tion of the I domain ofCD1 la within the Ile-Lys-Gly-Asn 
motif at positions 126-129, and that Lys-127 and Asn-129 
are critical to ICAM-3 binding (Fig. 2 C). 
It  is  interesting  to  note  that  the  Ile-Lys-Gly-Asn se- 
quence was previously found to be critical for the binding 
of several mAbs to murine and human CD11a that block 
binding to ICAM-1  (24). Although subsequent studies (28) 
demonstrated that these residues were not directly involved 
in ICAM-1  binding, the fact that an immediately adjacent 
sequence (residues 130-143) was highly conserved among 
the CD11 integrin I domains, as well as homologous domains 
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Figure 2.  LFA-l-mediated adhesion ofH/M CDlla I domain chimeras  and point mutants to purified human ICAM-1 and ICAM-3. 293 cells, trans- 
fected with pAdv RNA (mock) or together with wild-type human CD18 and the indicated CDlla constructs, were tested for their capacity to bind 
ICAM-I (white bars) and ICAM-3 (black bars) in the presence of 5--20 I~g/rnl  activating  anti-CD18 mAb (KIMI85) (12). (A) Adhesion of the mul, mu2, 
and mu3 chimeric proteins to human  ICAM-1 and ICAM-3. (B) Adhesion  of the H/M I domain  chimeras to human ICAM-1 and ICAM-3. (C and D) 
Adhesion of the I domain point mutants to human  ICAM-1 and ICAM-3. One representative  experiment out of three is shown. 
of other proteins (e.g., cartilage matrix protein, von WiUe- 
brand factor,  and factor B  [33]),  suggested  that this was  a 
functionally significant domain. Studies by Michishita et al. 
(19) showed that mutation of Asp-140GlySer to AlaGlyAla 
of the closely related integrin CD11b  abohshed binding to 
C3bi.  Recent x-ray  diffraction studies of the  I  domain  of 
Mac-1  have  shown Asp-140  and  Ser-142  to  be  part  of a 
novel cation binding site in which the acidic side chain co- 
ordinates directly to a Mg  2+ ion (34). Studies of CDlla  (28) 
have shown that the homologous Asp-137  in CD11a  was 
critical to ICAM-1 binding. We found that mutation of Asp- 
137 to Ala abrogated binding to ICAM-3 (Fig. 2 D). In con- 
trast, mutation of Ser-139 to Ala did not profoundly effect 
LFA-1 binding to ICAM-1  or ICAM-3, suggesting that Ser- 
139 of CD 1 la may not be involved in cation coordination. 
Since  the  residues  corresponding  to  the  Ile-Lys-Gly-Asn 
motif were absent from the Mac-1  I domain fragment used 
for the x-ray diffraction study (34), and since Mac-1  lacks a 
homologous sequence,  it will be  of interest  to  determine 
the structure and proximity of this motif to the CDlla  cat- 
ion binding site. 
To  obtain  further  insight into  the  role  of the  Ile-Lys- 
Gly-Asn-126 to 129 and the Asp-137 sequences in binding 
oflCAM-3  to LFA-1, a series ofpeptides that spanned this 
region  of CDlla  were  synthesized (Fig.  3).  Interestingly, 
we  observed  that low  concentrations  of one  peptide  effi- 
ciently inhibited the ability of the LFA-l-expressing T  cell 
clone HSB to bind to ICAM-3,  but not to ICAM-1  (pep- 
tide 2;  ICs0  =  25  p~g/ml;  10.8  ~,M).  In contrast,  the two 
other peptides  (peptides  1  and  3),  which also  contain  the 
Ile-Lys-Gly-Asn  motif,  did  not  inhibit  LFA-l-mediated 
adhesion at concentrations up to 100 ixg/ml. These data in- 
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Figure  3.  Inhibition  of LFA-1/ICAM-3-mediated  adhesion by low 
concentrations  of synthetic I domain  peptides. The LFA-1--expressing  HSB 
T cell clone was preincubated with different concentrations  of the indi- 
cated synthetic  peptides (6.25--200 Ixg/ml) followed by activation  with the 
anti-CD18 mAb KIM185 (10 ~g/ml). The capacity of the peptides to 
block binding to ICAM-1 or ICAM-3 was measured. Results are ex- 
pressed as the mean percentage of inhibition of cell binding from triplicate 
wells. Standard deviation was <8%. One representative experiment out 
of three is shown. 
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dicate that the sequences surrounding this motif are impor- 
tant for the inhibitory effect ofpeptide 2. Since ICAM-3 is 
thought to play a role in the initiation  of the immune re- 
sponse, we investigated whether the Ile-Lys-Gly-Asn-con- 
taining peptides also affected immune function. We assayed 
whether the peptides would inhibit either the ICAM-1 or 
ICAM-3/CD3-induced costimulation of resting PBL pro- 
liferation  (35).  As illustrated  in Fig.  4, peptide  2  inhibited 
ICAM-3--induced proliferation,  but  not  ICAM-l-induced 
proliferation.  Peptides  1 and 3  were inactive.  The inhibi- 
tory activity of the peptides is likely to result from binding 
of the peptide to residues of ICAM-3 that are involved in 
LFA-1 binding. This is currently under investigation. 
Comparison of the sequence homology of the I domains 
of the other CD18 integrins indicated that the Ile-Lys-Gly- 
Asn motif is unique to CDlla, suggesting that LFA-1 con- 
tains a unique binding site for ICAM-3. Indeed, no studies 
have  reported  Mac-l-  or  p150/95-mediated  binding  to 
ICAM-3 
3000  400O 
Figure  4.  Inhibition of ICAM-3  costimulation of 
PBL with I domain peptides. Resting PBL (100,000 
cells/well) were cultured in the presence of the syn- 
thetic peptides (100 I.Lg/ml; depicted in  Fig. 3)  on 
plates coated with ICAM-1Fc (white bars) and ICAM- 
3Fc  (black bars) (100 ng/weU) along with suboptimal 
concentrations ofanti-CD3 mAb (1 ng/well) for 3 d at 
37~  One experiment out of three, in which triplicate 
determinations were carried out, is shown. 
ICAM-3.  It will  be  interesting  to  know whether  the  re- 
cently  described  fourth  member  of the  CD18  integrins 
CD11d/CD18  contains  the  Ile-Lys-Gly-Asn sequence  in 
the I domain, since there is evidence that this heterodimer 
binds to ICAM-3 with high affinity (36). 
Collectively, these findings demonstrate for the first time 
that the I domain of CDlla  contains distinct functional sub- 
domains  for ligand-specific  binding:  a  conserved  Asp-137 
residue  important  for binding of ICAM-1  and -3,  an Ile- 
Lys-Gly-Asn domain  important  for binding  of ICAM-3, 
and distinct, yet-to-be-defined residues important for bind- 
ing of ICAM-1  (37).  Our finding that low concentrations 
of I domain peptides  significantly inhibit ICAM-3-depen- 
dent immune function, without affecting ICAM-l-depen- 
dent function, may direct the  development of a new class 
of antiinflammatory/immunosuppressive agents for the treat- 
ment of diseases such as arthritis or graft rejection after organ 
transplantation. 
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